Anesthetics:
Indications for: ATIVAN INJECTION
Preanesthetic to produce sedation, anxiety relief, and diminished recall of events related to surgery.
Adult Dosage:
Individualize. ≥18yrs: IM: Give 2 hours prior to surgery. 0.05mg/kg, max 4mg. IV: Give 15–20 minutes prior to surgery. 0.044mg/kg or 2mg total, whichever is lower, may increase dose to 0.05mg/kg up to max 4mg if diminished recall of events related to surgery is desired; >50yrs: max IV dose of 0.044mg/kg or 2mg total, whichever is lower.
Children Dosage:
<18yrs: not established.
ATIVAN INJECTION Contraindications:
Acute narrow-angle glaucoma. Sleep apnea. Severe respiratory insufficiency (except as preanesthetic during mechanical ventilation). Intra-arterial injection. Premature infants.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
ATIVAN INJECTION Warnings/Precautions:
Risks from concomitant use with opioids; see Interactions. Monitor for respiratory depression and level of sedation; ensure availability of resuscitative equipment for ventilatory support. Fall risk. Critically ill. Limited pulmonary reserve. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Drug or alcohol abuse. Hepatic or renal failure: not recommended; mild to moderate hepatic/renal disease: use with caution. Avoid extravasation. Outpatient endoscopy. Pediatric neurotoxicity. Elderly. Premature neonates/infants: gasping syndrome (due to benzyl alcohol content). Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Labor & delivery: not recommended. Nursing mothers: monitor infants.
ATIVAN INJECTION Classification:
Benzodiazepine.
ATIVAN INJECTION Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS effects with alcohol, phenothiazines, barbiturates, antidepressants, and MAOIs. Caution with concomitant scopolamine, loxapine, clozapine, haloperidol, or other CNS depressant drugs. May be antagonized by oral contraceptives (may need to increase lorazepam dose). May be potentiated by probenecid or valproate (reduce lorazepam dose by 50%).
Adverse Reactions:
Respiratory depression/failure, hypotension, somnolence, headache, apnea, excessive sleepiness and drowsiness, inj site reaction, paradoxical reactions; withdrawal reactions.
Drug Elimination:
Renal (88±4%), fecal (7±2%). Terminal half-life: 14±5 hours.
Generic Drug Availability:
YES
How Supplied:
Single-use vials—10, 25; Multiple-dose vials (10mL)—10, 25
Seizure disorders:
Indications for: ATIVAN INJECTION
Status epilepticus.
Adult Dosage:
Individualize. ≥18yrs: Give by IV inj. 4mg at a rate of 2mg/min; may repeat dose once in 10–15 minutes if seizures continue or recur.
Children Dosage:
<18yrs: not established.
ATIVAN INJECTION Contraindications:
Acute narrow-angle glaucoma. Sleep apnea. Severe respiratory insufficiency (except as preanesthetic during mechanical ventilation). Intra-arterial injection. Premature infants.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
ATIVAN INJECTION Warnings/Precautions:
Risks from concomitant use with opioids; see Interactions. Monitor for respiratory depression and level of sedation; ensure availability of resuscitative equipment for ventilatory support. Fall risk. Critically ill. Limited pulmonary reserve. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Drug or alcohol abuse. Hepatic or renal failure: not recommended; mild to moderate hepatic/renal disease: use with caution. Avoid extravasation. Outpatient endoscopy. Pediatric neurotoxicity. Elderly. Premature neonates/infants: gasping syndrome (due to benzyl alcohol content). Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Labor & delivery: not recommended. Nursing mothers: monitor infants.
ATIVAN INJECTION Classification:
Benzodiazepine.
ATIVAN INJECTION Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS effects with alcohol, phenothiazines, barbiturates, antidepressants, and MAOIs. Caution with concomitant scopolamine, loxapine, clozapine, haloperidol, or other CNS depressant drugs. May be antagonized by oral contraceptives (may need to increase lorazepam dose). May be potentiated by probenecid or valproate (reduce lorazepam dose by 50%).
Adverse Reactions:
Respiratory depression/failure, hypotension, somnolence, headache, apnea, excessive sleepiness and drowsiness, inj site reaction, paradoxical reactions; withdrawal reactions.
Drug Elimination:
Renal (88±4%), fecal (7±2%). Terminal half-life: 14±5 hours.
Generic Drug Availability:
YES
How Supplied:
Single-use vials—10, 25; Multiple-dose vials (10mL)—10, 25
